Palliative prostate radiotherapy for symptomatic advanced prostate cancer

Radiotherapy and Oncology

Volumn 93, Issue 2, 2009, Pages 192-196

  Din, Omar S ^a   Thanvi, Narottam ^a   Ferguson, Catherine J ^a   Kirkbride, Peter ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Palliative; Prostate; Radiotherapy; Symptomatic

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; DEMOGRAPHY; DIARRHEA; HEMATURIA; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE FRACTIONATION; RATING SCALE; RETROSPECTIVE STUDY; SKIN MANIFESTATION; TENESMUS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT OBSTRUCTION; VOMITING;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 70350512367     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.04.017     Document Type: Article

References (20)

1. NICE Clinical Guideline: prostate cancer. London: National Collaborating Centre for Cancer; 2008.
2. Toms JR. Cancerstats monograph. London: Cancer Research UK; 2004.
3. Ross R.W., Xie W., Regan M.M., et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 112 (2008) 1247-1253
4. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
5. Hindson B., Turner S., and Do V. Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Australas Radiol 51 (2007) 584-588
6. Lankford S.P., Pollack A., and Zagars G.K. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33 (1995) 907-912
7. Nakamura K., Teshima T., Takahashi Y., et al. Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer Res 24 (2004) 3141-3145
8. Furuya Y., Akakura K., Akimoto S., Ichikawa T., and Ito H. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol 6 (1999) 187-191
9. Kawakami S., Kawai T., Yonese J., Yamauchi T., Ishibashi K., and Ueda T. Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer. Nippon Hinyokika Gakkai Zasshi 84 (1993) 1681-1684
10. Hernes E.H., Linja M., Fossa S.D., et al. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int 86 (2000) 240-247
11. Clarke N.W. The management of hormone-relapsed prostate cancer. BJU Int 92 (2003) 860-868
12. Mazur A.W., and Thompson I.M. Efficacy and morbidity of channel TURP. Urology 38 (1991) 526-528
13. Crain D.S., Amling C.L., and Kane C.J. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171 (2004) 668-671
14. Gnanapragasam V.J., Kumar V., Langton D., Pickard R.S., and Leung H.Y. Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer. Int J Urol 13 (2006) 711-715
15. Morioka M., Kobayashi T., Furukawa Y., et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int 68 (2002) 10-15
16. Nishimura K., Nonomura N., Yasunaga Y., et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89 (2000) 2570-2576
17. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
18. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
19. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
20. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520